Oligometastatic Prostate Cancer: A Multidisciplinary Approach to Patient Care

This activity is a case-based discussion with a panel of experts in the field of GU malignancies discussing how to personalize treatment recommendations based on imaging (including MRI, Fluciclovine F18 and Ga68-PSMA scans), pathology and clinical findings for patients with oligometastatic disease. For this activity, we have a multidisciplinary panel featuring radiation oncologists, medical oncology as well as radiology. A series of cases are presented and there is an opportunity for each panelist to discuss their focus of interest (systemic treatment, radiation or evaluation of imaging ex. PSMA PET) and how they would approach each case. There is a clear need to provide a real-world activity to discuss challenging cases in the oligometastatic space that are of great relevance to radiation oncologists. The goal is to present the latest cutting-edge research and to explain and provide context for management decisions for patients with oligometastatic prostate cancer.   

Topics:

  1. Radiation in the Oligometastatic Setting for Prostate Cancer
    Shalini Moningi, MD  
  2. Systemic Therapy for Oligometastatic Prostate Cancer
    Atish Choudhury, MD, PhD 
  3. The Role of Advanced Imaging and Theranostics in Oligometastatic and Metastatic Prostate Cancer
    Delphine Chen, MD
  4. Conclusion
    Shalini Moningi, MD

This activity is available from August 5, 2025, through 11:59 p.m. Eastern time on August 4, 2027. 

Target Audience

The activity is designed to meet the interests of radiation biologists and residents.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Learn and be exposed to different approaches to treating patients with oligometastatic prostate cancer, depending on the clinical situation. 
  • Analyze data including imaging, pathology and clinical data in this setting. 
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.
Course opens: 
08/05/2025
Course expires: 
08/04/2027
Cost:
$149.00
Rating: 
0
  • Shalini Moningi, MD, is employed by the Cleveland Clinic. 
  • Atish Choudhury, MD, PhD, is employed by the Dana-Farber Cancer Institute/Harvard Medical School. Dr. Choudhury receives honoraria from OncLive, Targeted Oncology, Aptitude Health, Great Debates and Updates, Pfizer, Springer, Lantheus, Wiley, Color Genomics, Physicians' Education Resource, Outcomes4Me, DAVA Oncology, Medscape and MDoutlook. Dr. Choudhury serves on the advisory boards of Tolmar, Janssen/Johnson & Johnson, Sanofi Aventis, Pfizer, Astellas, Bayer, Daiichi Sankyo and Boundless Bio. Dr. Choudhury receives institutional research funding from Merck, Bayer, Eli Lilly, Pfizer and Sumitomo Pharma America. 
  • Delphine Chen, MD, is employed by the University of Washington - Fred Hutchinson Cancer Center. Dr. Chen receives clinical trial funding/grant funding from AstraZeneca, Imaginab, Nihon, NIH and United Imaging. Dr. Chen receives honoraria and travel expenses from GE Healthcare and OncLive. Dr. Chen receives in-kind funding from Telix Pharmaceuticals.   

The person(s) above served as the developer(s) of this activity. Additionally, the ASTRO Education Committee had control over the content of this activity. All relevant financial relationships have been mitigated.

Disclosure link: 
ASTRO Education Committee

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.

Price

Cost:
$149.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.

  • Nonmember: $149
  • Member: $99
  • Member-in-Training: $49
  • Student/Graduate Student/PGY-1 Member: $49
  • Postdoctoral Fellow Member: $49

If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.

Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date. 

Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.

The activity and its materials will only be available on the ASTRO website until August 4, 2027, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date. 

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.